Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 3/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899576 | 0.83 | ACHE (0.46) | ACHEPYCR1MAOAMAOBDRD2 | |
| SCHEMBL6267123 | 0.83 | ACHE (0.43) | ACHEMAOAMAOBDRD2HTR2A | |
| SCHEMBL10820372 | 0.80 | MAOA (0.56) | ACHEMAOAMAOB | |
| SCHEMBL6262149 | 0.79 | MAOA (0.59) | ACHEPYCR1HSP90AA1MAOAMAOB | |
| SCHEMBL8788691 | 0.77 | ALDH1A1 (0.43) | — | |
| SCHEMBL14053434 | 0.72 | GRIN2B (0.39) | HSP90AA1PNMTADRA2A | |
| SCHEMBL29113464 | 0.70 | ACHE (0.49) | ACHEHSP90AA1PNMTADRA2A | |
| SCHEMBL6263299 | 0.69 | KMT2A (0.45) | HSP90AA1KDM1ANR3C1DRD2PNMT | |
| SCHEMBL5899524 | 0.67 | MAOA (0.62) | ACHEMAOAMAOB | |
| SCHEMBL3300396 | 0.66 | ACHE (0.49) | ACHEMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197365-A1 | Diamino thiazoloindan derivatives and their use | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197365-A1 | Diamino thiazoloindan derivatives and their use | RTN3, RTN4, DRD4 | ACHE 3951/4885PYCR1 1554/4885HSP90AA1 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.